case_images: PMC10565213_01
case_images: Patient 1. Contrast-enhanced computed tomography (CT) of the chest (A, B) abdomen and pelvis (C) at time of diagnosis demonstrates a left upper lobe paramediastinal mass (arrow), a right lower lobe lung nodule (arrowhead) and an enhancing solid right rectus sheath mass (curved arrow), fluorodeoxyglucose (FDG)-avid on a FDG positron emission tomography (PET)/CT (D) obtained at the same time. After treatment with vincristine/adriamycin/Ifosfamide, resection of the rectus sheath mass and radiation to the left lung mass, the patient started treatment with Pazopanib. Magnified view of an axial contrast-enhanced CT image of the chest (E) obtained before patient started treatment with Pazopanib shows the right lung nodule (arrowhead), and a new enhancing left paramediastinal mass (arrow), both showing mildly decreased size and enhancement on CT obtained 28 months after starting treatment (F), suggesting tumor regression.
case_images: fonc-13-1215003-g001.jpg
case_images: PMC10565213_01_fonc-13-1215003-g001.jpg
case_images: f1
case_images: Computed tomography (CT) chest, abdomen, and pelvis and fluorodeoxyglucose-positron emission tomography/CT (FDG PET/CT) showed multiple FDG-avid sites of disease, including multiple lung nodules, an 8-cm mass in the left upper lung lobe with direct extension to the mediastinum, and a 2.7-cm right rectus sheath mass ( Figures 1A-C ).
case_images: PMC10565213_02
case_images: Patient 2. Contrast-enhanced computed tomography (CT) of the abdomen and pelvis at time of the symptoms (A) demonstrates a large pelvic mass with solid and cystic components (arrow), left upper quadrant peritoneal stranding, and peritoneal thickening (arrowhead). Patient underwent exploratory laparotomy revealing a ruptured pelvic mass and a small bowel tumor. After treatment with vincristine/adriamycin/cytoxan/olaratumab, the patient started treatment with pazopanib and underwent palliative radiation to the pelvis. Contrast-enhanced CT of the abdomen and pelvis obtained before patient started treatment with pazopanib (B) shows an enhancing solid and cystic pelvic mass (arrow) and an enhancing solid and cystic right upper quadrant mass (curved arrow), both showing decreased enhancement on contrast-enhanced CT obtained 17 months after starting treatment (C). A contrast-enhanced CT of the abdomen and pelvis obtained 23 months after starting pazopanib (D) and shows a new large enhancing solid and cystic left upper quadrant mass (dashed arrow) suggesting progression of disease. .
case_images: fonc-13-1215003-g003.jpg
case_images: PMC10565213_02_fonc-13-1215003-g003.jpg
case_images: f3
case_images: There was also evidence of ascites ( Figure 3A ).